KIO-104

Phase 2Small molecule

KKiora Pharmaceuticals, Inc.

KIO-104 is one of 2 small molecule programs targeting Macular Edema. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Macular EdemaRecruiting

Macular EdemaPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Macular Edema

#DrugCompanyPhaseTrials

KIO-104

KKiora Pharmaceuticals, Inc.

Phase 2

1 2

CU06-1004

CCuracle Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Macular Edema

NCT06825702

Clinical

Trials by Indication[1]

Macular Edema1 trial

A Phase 2, Open-label, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema (KLARITY-1)

Recruiting·KKiora Pharmaceuticals, Inc.·Phase 2·NCT06825702·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KIO-104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KIO-104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KIO-104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kiora Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKiora Pharmaceuticals, Inc.

KIO-104

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Macular Edema1 trial

References

Drug Info

Quick Facts

Related News